Baby-CINO: CaffeINe Treatment Optimisation in Premature Infants (Baby-CINO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Caroline Hartley
- Phone Number: +44 1865 234537
- Email: caroline.hartley@paediatrics.ox.ac.uk
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 9DU
- Recruiting
- Newborn Care Unit, John Radcliffe Hospital
-
Contact:
- Caroline Hartley
- Phone Number: +44 1865 234537
- Email: caroline.hartley@paediatrics.ox.ac.uk
-
Principal Investigator:
- Caroline Hartley, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Born to a mother aged 16 or over
- Admitted to the Newborn Care Unit, John Radcliffe Hospital
- Born prematurely (before 37 weeks' gestation)
- Parent given informed written consent
- Receiving caffeine citrate
Exclusion Criteria:
- Known chromosomal abnormality or life-threatening congenital abnormality
- Severe hypoxic insult at birth
- Intraventricular haemorrhage grade III or IV or other severe neurological pathology
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Preterm infant
Preterm infants receiving caffeine (prescribed clinically) will be studied
|
We will record infant's brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped.
The decision to change dose/stop treatment will be made by the clinical team as part of routine care.
No changes in caffeine treatment will be carried out solely for research purposes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Respiration
Time Frame: From baseline to two days later
|
Change in respiratory dynamics between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later
|
From baseline to two days later
|
|
Brain activity
Time Frame: From baseline to two days later
|
Change in EEG activity between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later
|
From baseline to two days later
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate
Time Frame: From baseline to two days later
|
Change in heart rate between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later
|
From baseline to two days later
|
|
Oxygen saturation
Time Frame: From baseline to two days later
|
Change in oxygen saturation between baseline (time at which caffeine dose is changed/treatment ends) and approximately 2 days later
|
From baseline to two days later
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Caroline Hartley, University of Oxford
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Premature Birth
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Central Nervous System Stimulants
- Caffeine
Other Study ID Numbers
Other Study ID Numbers
- PID17161
- 23/SC/0397 (Other Identifier: Research Ethics Committee)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.